Biocon Biologics Expands Oncology Portfolio with New Biosimilars

Biocon Biologics Ltd., a subsidiary of Biocon Ltd., has announced the expansion of its oncology biosimilar portfolio. The company will introduce new biosimilars for Trastuzumab/Hyaluronidase (Herceptin® SC/Herceptin HYLECTA™), Nivolumab (Opdivo®), and Pembrolizumab (Keytruda®) at the 2026 J.P. Morgan Healthcare Conference. This expansion is part of Biocon Biologics’ strategy to broaden its comprehensive cancer portfolio and increase access to cost-effective oncology therapies.

The company will integrate as a wholly owned subsidiary of Biocon Ltd., which is expected to be completed by March 31, 2026. This integration aims to leverage Biocon’s global commercial infrastructure, simplifying the corporate structure and enhancing its position in diabetes, oncology, and immunology. The integration will enable Biocon to offer both biosimilar insulins and generics for complex peptides, including GLP-1s, addressing the full spectrum of diabetes care.

Biocon Biologics plans to unveil three new biosimilar oncology assets at the 2026 J.P. Morgan Healthcare Conference. These assets include two PD-1 inhibitors, which will join the company’s existing portfolio of 17 oncology medications. The new biosimilars are among the largest oncology biologics scheduled to lose exclusivity over the next five years. The company’s oncology portfolio represents an over $75 billion opportunity, accounting for approximately 35% of the global oncology pharmaceutical market.

The integration of Biocon Biologics as a wholly owned subsidiary is expected to be completed by March 31, 2026. Post-integration, Shreehas Tambe will take on the role of CEO & Managing Director of the combined business. The integration will enhance Biocon Biologics’ ability to deliver innovative, affordable medicines to over 6 million patients in more than 120 markets worldwide.

Biocon Biologics Ltd. is a fully integrated global biosimilars company and a subsidiary of Biocon Ltd. The company is committed to transforming healthcare by providing affordable access to high-quality biosimilars. It serves over 6 million patients across 120 countries, leveraging cutting-edge science and global scale manufacturing capabilities.

Biocon Ltd. is an innovation-led global biopharmaceuticals company focused on enhancing affordable access to complex therapies for chronic conditions like diabetes, cancer, and autoimmune diseases. The company has developed and commercialized novel biologics, biosimilars, and complex small molecule APIs in India and several key global markets.